Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Intraductal, Noninfiltrating | 22 | 2024 | 934 | 5.980 |
Why?
|
Breast Neoplasms | 68 | 2025 | 21156 | 3.680 |
Why?
|
Carcinoma, Ductal, Breast | 11 | 2021 | 1092 | 3.130 |
Why?
|
Mastectomy, Segmental | 24 | 2024 | 961 | 2.730 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2024 | 9425 | 2.050 |
Why?
|
Decision Support Techniques | 16 | 2024 | 2010 | 1.920 |
Why?
|
Mastectomy | 16 | 2024 | 1852 | 1.790 |
Why?
|
Radiotherapy, Adjuvant | 16 | 2024 | 1794 | 1.680 |
Why?
|
Carcinoma in Situ | 3 | 2021 | 791 | 1.320 |
Why?
|
Markov Chains | 17 | 2020 | 977 | 1.220 |
Why?
|
Receptors, Estrogen | 11 | 2025 | 2243 | 1.190 |
Why?
|
Radiosurgery | 5 | 2016 | 1354 | 1.160 |
Why?
|
Tamoxifen | 7 | 2023 | 968 | 1.140 |
Why?
|
SEER Program | 16 | 2024 | 1476 | 1.040 |
Why?
|
Receptors, Progesterone | 7 | 2025 | 1145 | 0.990 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2013 | 1536 | 0.930 |
Why?
|
Quality-Adjusted Life Years | 9 | 2018 | 1734 | 0.770 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2018 | 811 | 0.750 |
Why?
|
Combined Modality Therapy | 20 | 2021 | 8559 | 0.720 |
Why?
|
Neoplasm Staging | 24 | 2024 | 11249 | 0.670 |
Why?
|
Decision Making | 5 | 2024 | 3961 | 0.670 |
Why?
|
Aromatase Inhibitors | 3 | 2008 | 518 | 0.610 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2020 | 3550 | 0.580 |
Why?
|
Receptor, erbB-2 | 7 | 2025 | 2586 | 0.570 |
Why?
|
Neoplasms, Second Primary | 3 | 2024 | 1062 | 0.530 |
Why?
|
Prostate-Specific Antigen | 4 | 2007 | 2483 | 0.520 |
Why?
|
Cost-Benefit Analysis | 12 | 2020 | 5532 | 0.510 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2016 | 5426 | 0.490 |
Why?
|
Patient Participation | 2 | 2015 | 1450 | 0.490 |
Why?
|
Aged | 58 | 2024 | 171520 | 0.460 |
Why?
|
Female | 78 | 2025 | 396943 | 0.450 |
Why?
|
Middle Aged | 60 | 2025 | 223418 | 0.440 |
Why?
|
Cranial Irradiation | 1 | 2016 | 395 | 0.430 |
Why?
|
Mastectomy, Modified Radical | 1 | 2013 | 62 | 0.430 |
Why?
|
Secondary Prevention | 2 | 2023 | 1479 | 0.420 |
Why?
|
Quality of Life | 6 | 2024 | 13497 | 0.410 |
Why?
|
Sentinel Lymph Node Biopsy | 5 | 2025 | 743 | 0.400 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2018 | 493 | 0.400 |
Why?
|
Lymph Node Excision | 4 | 2014 | 1276 | 0.400 |
Why?
|
Cytochrome P-450 CYP2D6 | 2 | 2013 | 108 | 0.400 |
Why?
|
Patient Preference | 1 | 2019 | 948 | 0.390 |
Why?
|
Comparative Effectiveness Research | 2 | 2014 | 712 | 0.380 |
Why?
|
Radiotherapy | 7 | 2024 | 1510 | 0.370 |
Why?
|
Humans | 95 | 2025 | 768451 | 0.360 |
Why?
|
Carcinoma, Lobular | 3 | 2022 | 480 | 0.360 |
Why?
|
Models, Economic | 2 | 2017 | 717 | 0.350 |
Why?
|
Radiation Oncology | 4 | 2023 | 573 | 0.350 |
Why?
|
Mammaplasty | 4 | 2024 | 1262 | 0.350 |
Why?
|
Prostatic Neoplasms | 6 | 2018 | 11206 | 0.330 |
Why?
|
Disease-Free Survival | 9 | 2015 | 6856 | 0.330 |
Why?
|
Lung Neoplasms | 6 | 2024 | 13589 | 0.330 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2018 | 4083 | 0.310 |
Why?
|
Aged, 80 and over | 30 | 2024 | 59680 | 0.310 |
Why?
|
Estrogen Receptor Modulators | 1 | 2008 | 58 | 0.300 |
Why?
|
Tumor Burden | 5 | 2018 | 1909 | 0.300 |
Why?
|
Neck Dissection | 1 | 2009 | 201 | 0.300 |
Why?
|
Prognosis | 15 | 2025 | 30028 | 0.300 |
Why?
|
Adult | 42 | 2024 | 223542 | 0.290 |
Why?
|
Postmenopause | 5 | 2024 | 2519 | 0.290 |
Why?
|
Neoplasm Invasiveness | 6 | 2018 | 3637 | 0.270 |
Why?
|
Brachytherapy | 2 | 2011 | 1227 | 0.270 |
Why?
|
Brain Neoplasms | 4 | 2017 | 9182 | 0.270 |
Why?
|
Survival Analysis | 8 | 2019 | 10125 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 11843 | 0.260 |
Why?
|
Treatment Outcome | 16 | 2024 | 65409 | 0.250 |
Why?
|
Computer Simulation | 4 | 2018 | 6278 | 0.250 |
Why?
|
Insurance, Liability | 2 | 2017 | 100 | 0.250 |
Why?
|
Lymphatic Metastasis | 7 | 2018 | 2930 | 0.240 |
Why?
|
Survivors | 3 | 2010 | 2381 | 0.240 |
Why?
|
Guideline Adherence | 2 | 2011 | 2239 | 0.230 |
Why?
|
Follow-Up Studies | 14 | 2024 | 39430 | 0.230 |
Why?
|
Age Factors | 9 | 2018 | 18478 | 0.220 |
Why?
|
Postoperative Period | 2 | 2016 | 1833 | 0.210 |
Why?
|
Estrogen Antagonists | 1 | 2003 | 150 | 0.210 |
Why?
|
Prostatic Hyperplasia | 1 | 2006 | 523 | 0.200 |
Why?
|
Healthcare Disparities | 3 | 2022 | 3412 | 0.190 |
Why?
|
Axilla | 4 | 2024 | 629 | 0.190 |
Why?
|
Selection Bias | 1 | 2003 | 360 | 0.190 |
Why?
|
Radiotherapy Dosage | 6 | 2015 | 2925 | 0.190 |
Why?
|
Malpractice | 2 | 2017 | 561 | 0.180 |
Why?
|
Breast | 2 | 2022 | 1976 | 0.180 |
Why?
|
Stomach Neoplasms | 1 | 2011 | 1484 | 0.180 |
Why?
|
Breast Implants | 1 | 2024 | 414 | 0.180 |
Why?
|
Logistic Models | 8 | 2017 | 13324 | 0.170 |
Why?
|
United States | 15 | 2024 | 73121 | 0.170 |
Why?
|
Risk Assessment | 5 | 2024 | 24311 | 0.160 |
Why?
|
Health Care Costs | 2 | 2011 | 3265 | 0.160 |
Why?
|
Odds Ratio | 6 | 2017 | 9687 | 0.160 |
Why?
|
Depression | 1 | 2018 | 8235 | 0.160 |
Why?
|
Prostate | 2 | 2005 | 1781 | 0.160 |
Why?
|
Dysgeusia | 1 | 2018 | 15 | 0.150 |
Why?
|
Internet | 2 | 2024 | 3123 | 0.150 |
Why?
|
Research Design | 1 | 2014 | 6217 | 0.150 |
Why?
|
Propensity Score | 2 | 2016 | 1971 | 0.150 |
Why?
|
Xerostomia | 1 | 2018 | 94 | 0.150 |
Why?
|
Mass Screening | 2 | 2010 | 5455 | 0.140 |
Why?
|
Catheter Ablation | 1 | 2011 | 2775 | 0.140 |
Why?
|
Survival Rate | 7 | 2025 | 12875 | 0.140 |
Why?
|
Risk | 3 | 2019 | 9642 | 0.140 |
Why?
|
Carboplatin | 1 | 2020 | 798 | 0.140 |
Why?
|
Breast Implantation | 1 | 2019 | 224 | 0.140 |
Why?
|
Neoplasm, Residual | 3 | 2017 | 1014 | 0.130 |
Why?
|
Sensitivity and Specificity | 5 | 2018 | 14728 | 0.130 |
Why?
|
Lymphedema | 1 | 2002 | 527 | 0.130 |
Why?
|
Frozen Sections | 1 | 2016 | 155 | 0.120 |
Why?
|
Gastrostomy | 1 | 2018 | 325 | 0.120 |
Why?
|
Head and Neck Neoplasms | 1 | 2009 | 2915 | 0.120 |
Why?
|
Retrospective Studies | 12 | 2022 | 81834 | 0.120 |
Why?
|
Endothelial Growth Factors | 1 | 1997 | 674 | 0.120 |
Why?
|
Cisplatin | 1 | 2021 | 1661 | 0.120 |
Why?
|
Time Factors | 8 | 2017 | 40271 | 0.120 |
Why?
|
Chemoprevention | 1 | 2017 | 326 | 0.120 |
Why?
|
Doxorubicin | 2 | 2020 | 2229 | 0.120 |
Why?
|
Lymphokines | 1 | 1997 | 927 | 0.120 |
Why?
|
Carcinoma | 1 | 2006 | 2341 | 0.120 |
Why?
|
Cyclophosphamide | 1 | 2020 | 2224 | 0.110 |
Why?
|
Adenocarcinoma | 1 | 2011 | 6400 | 0.110 |
Why?
|
Mammography | 3 | 2018 | 2436 | 0.110 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6657 | 0.100 |
Why?
|
Watchful Waiting | 1 | 2017 | 496 | 0.100 |
Why?
|
Fear | 1 | 2021 | 1494 | 0.100 |
Why?
|
Medicare | 3 | 2022 | 6881 | 0.100 |
Why?
|
Multivariate Analysis | 4 | 2011 | 12096 | 0.100 |
Why?
|
Extremities | 1 | 2017 | 870 | 0.100 |
Why?
|
Withholding Treatment | 1 | 2015 | 621 | 0.090 |
Why?
|
Radiation Injuries | 2 | 2017 | 1205 | 0.090 |
Why?
|
Neoplasm Metastasis | 3 | 2015 | 4931 | 0.090 |
Why?
|
Reoperation | 3 | 2017 | 4342 | 0.090 |
Why?
|
Risk Factors | 7 | 2024 | 74915 | 0.090 |
Why?
|
Cohort Studies | 6 | 2022 | 41797 | 0.090 |
Why?
|
Male | 18 | 2020 | 364781 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 4 | 2015 | 20762 | 0.090 |
Why?
|
Hodgkin Disease | 2 | 2009 | 1386 | 0.090 |
Why?
|
Utilization Review | 1 | 2011 | 384 | 0.090 |
Why?
|
Residence Characteristics | 1 | 2020 | 2119 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 1997 | 1943 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2020 | 1439 | 0.080 |
Why?
|
Biopsy | 3 | 2007 | 6816 | 0.080 |
Why?
|
Prospective Studies | 8 | 2024 | 54914 | 0.080 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2015 | 1680 | 0.080 |
Why?
|
Monte Carlo Method | 1 | 2014 | 1262 | 0.080 |
Why?
|
Practice Guidelines as Topic | 3 | 2011 | 7451 | 0.080 |
Why?
|
Health Services Accessibility | 1 | 2006 | 5510 | 0.080 |
Why?
|
Medical Errors | 1 | 2017 | 1263 | 0.080 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 2896 | 0.080 |
Why?
|
Analysis of Variance | 3 | 2011 | 6242 | 0.080 |
Why?
|
Lymph Nodes | 3 | 2016 | 3472 | 0.070 |
Why?
|
Xanthenes | 1 | 2007 | 71 | 0.070 |
Why?
|
Urinary Bladder | 1 | 2014 | 1160 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2006 | 4861 | 0.070 |
Why?
|
Insurance, Health | 1 | 2020 | 2513 | 0.070 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2008 | 131 | 0.070 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 549 | 0.070 |
Why?
|
Disease Progression | 3 | 2018 | 13655 | 0.070 |
Why?
|
Seminoma | 1 | 2008 | 136 | 0.070 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2018 | 1755 | 0.070 |
Why?
|
Models, Statistical | 3 | 2018 | 5103 | 0.070 |
Why?
|
Patient Satisfaction | 1 | 2019 | 3484 | 0.070 |
Why?
|
ROC Curve | 2 | 2005 | 3624 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 13708 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2013 | 1539 | 0.070 |
Why?
|
Gastrectomy | 1 | 2011 | 696 | 0.070 |
Why?
|
Sarcoma | 1 | 2017 | 1806 | 0.060 |
Why?
|
Papillomavirus Infections | 1 | 2018 | 1638 | 0.060 |
Why?
|
Primary Prevention | 1 | 2013 | 1189 | 0.060 |
Why?
|
Neoplasms | 2 | 2017 | 22386 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2012 | 15880 | 0.060 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2008 | 410 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2339 | 0.060 |
Why?
|
Frail Elderly | 1 | 2011 | 774 | 0.060 |
Why?
|
Young Adult | 8 | 2024 | 60045 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2013 | 8051 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9507 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 12561 | 0.060 |
Why?
|
Incidence | 3 | 2024 | 21552 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2010 | 15460 | 0.060 |
Why?
|
Pain Measurement | 1 | 2014 | 3577 | 0.060 |
Why?
|
Mortality | 1 | 2015 | 2917 | 0.060 |
Why?
|
Cancer Care Facilities | 1 | 2006 | 424 | 0.050 |
Why?
|
Databases, Factual | 2 | 2015 | 8081 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 36840 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5909 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8635 | 0.050 |
Why?
|
Nitriles | 1 | 2007 | 984 | 0.050 |
Why?
|
Testicular Neoplasms | 1 | 2008 | 806 | 0.050 |
Why?
|
Heart | 1 | 2015 | 4451 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4077 | 0.050 |
Why?
|
Depressive Disorder, Major | 1 | 2019 | 4816 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2012 | 7863 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2009 | 20231 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5442 | 0.040 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2024 | 555 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2006 | 2103 | 0.040 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2024 | 451 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 1997 | 11930 | 0.040 |
Why?
|
Registries | 2 | 2012 | 8373 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4941 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4615 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 890 | 0.040 |
Why?
|
Lipids | 1 | 2009 | 3346 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2019 | 160 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 13026 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2533 | 0.040 |
Why?
|
Genotype | 2 | 2013 | 13047 | 0.040 |
Why?
|
Pigment Epithelium of Eye | 1 | 1997 | 209 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2018 | 300 | 0.030 |
Why?
|
Lung | 1 | 2015 | 10090 | 0.030 |
Why?
|
Epidemiologic Factors | 1 | 2015 | 36 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 1997 | 868 | 0.030 |
Why?
|
Culture Media, Conditioned | 1 | 1997 | 522 | 0.030 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1997 | 750 | 0.030 |
Why?
|
Population Surveillance | 1 | 2006 | 2601 | 0.030 |
Why?
|
Blotting, Northern | 1 | 1997 | 1553 | 0.030 |
Why?
|
Life Expectancy | 2 | 2017 | 1249 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2018 | 6537 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2150 | 0.030 |
Why?
|
Receptor, IGF Type 1 | 1 | 1997 | 384 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 1997 | 661 | 0.030 |
Why?
|
Inhalation | 1 | 2015 | 145 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2016 | 513 | 0.030 |
Why?
|
Decision Trees | 1 | 2017 | 510 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2014 | 10358 | 0.030 |
Why?
|
Lymphatic Irradiation | 1 | 2014 | 115 | 0.030 |
Why?
|
Capillaries | 1 | 1997 | 756 | 0.030 |
Why?
|
Models, Theoretical | 1 | 2006 | 3590 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 1766 | 0.030 |
Why?
|
Organs at Risk | 1 | 2015 | 368 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 1007 | 0.030 |
Why?
|
Adolescent | 4 | 2017 | 89168 | 0.020 |
Why?
|
Income | 1 | 2020 | 1878 | 0.020 |
Why?
|
Mutation | 2 | 2022 | 30243 | 0.020 |
Why?
|
Thoracic Wall | 1 | 2012 | 204 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2286 | 0.020 |
Why?
|
Cell Division | 1 | 1997 | 4479 | 0.020 |
Why?
|
Kinetics | 1 | 1997 | 6348 | 0.020 |
Why?
|
Recurrence | 1 | 2022 | 8510 | 0.020 |
Why?
|
Antibodies | 1 | 1997 | 2425 | 0.020 |
Why?
|
Brain | 1 | 2016 | 27438 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1226 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2015 | 1277 | 0.020 |
Why?
|
Urban Population | 1 | 2016 | 2047 | 0.020 |
Why?
|
Analgesics | 1 | 2014 | 1070 | 0.020 |
Why?
|
Medicine | 1 | 2015 | 946 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 1997 | 3520 | 0.020 |
Why?
|
Orchiectomy | 1 | 2008 | 466 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 1997 | 5803 | 0.020 |
Why?
|
Bleomycin | 1 | 2006 | 495 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 1997 | 4425 | 0.020 |
Why?
|
Reimbursement Mechanisms | 1 | 2011 | 677 | 0.020 |
Why?
|
Rural Population | 1 | 2016 | 2317 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5880 | 0.020 |
Why?
|
Vinblastine | 1 | 2006 | 488 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2014 | 2433 | 0.020 |
Why?
|
Regression Analysis | 1 | 2014 | 6353 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2022 | 22293 | 0.010 |
Why?
|
Dacarbazine | 1 | 2006 | 560 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2015 | 26351 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8753 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1997 | 12813 | 0.010 |
Why?
|
Comorbidity | 1 | 2015 | 10601 | 0.010 |
Why?
|
Observer Variation | 1 | 2007 | 2622 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 3611 | 0.010 |
Why?
|
Mice | 1 | 1997 | 82045 | 0.010 |
Why?
|
Animals | 1 | 1997 | 169418 | 0.000 |
Why?
|